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Abstract
The disease-associated prion protein (PrP
TSE) ,t h ep r o b a b l ee t i o l o g i c a la g e n to f the transmissible spongiform
encephalopathies (TSEs), is resistant to degradation and can persist in the environment. Lichens, mutualistic symbioses
containing fungi, algae, bacteria and occasionally cyanobacteria, are ubiquitous in the environment and have evolved
unique biological activities allowing their survival in challenging ecological niches. We investigated PrP
TSE inactivation by
lichens and found acetone extracts of three lichen species (Parmelia sulcata, Cladonia rangiferina and Lobaria pulmonaria)
have the ability to degrade prion protein (PrP) from TSE-infected hamsters, mice and deer. Immunoblots measuring PrP
levels and protein misfolding cyclic amplification indicated at least two logs of reductions in PrP
TSE. Degradative activity was
not found in closely related lichen species or in algae or a cyanobacterium that inhabit lichens. Degradation was blocked by
Pefabloc SC, a serine protease inhibitor, but not inhibitors of other proteases or enzymes. Additionally, we found that PrP
levels in PrP
TSE-enriched preps or infected brain homogenates are also reduced following exposure to freshly-collected P.
sulcata or an aqueous extract of the lichen. Our findings indicate that these lichen extracts efficiently degrade PrP
TSE and
suggest that some lichens could have potential to inactivate TSE infectivity on the landscape or be a source for agents to
degrade prions. Further work to clone and characterize the protease, assess its effect on TSE infectivity and determine which
organism or organisms present in lichens produce or influence the protease activity is warranted.
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Introduction
Transmissible spongiform encephalopathies (TSEs) are a group
of infectious, neurodegenerative diseases including bovine spongi-
form encephalopathy, sheep scrapie, cervid chronic wasting
disease (CWD) and human Creutzfeldt-Jakob disease (CJD) [1].
The etiological agent of TSEs appears to be primarily, if not
exclusively, a misfolded isoform of the prion protein (PrP), termed
PrP
TSE [2]. The PrP
TSE protein and TSE infectivity exhibit
remarkable stability compared to typical pathogens and resist
conventional decontamination methods such as autoclaving and
disinfectants [3]. The resilience of TSE infectivity to inactivation
has led to unexpected instances of disease transmission, such as
CJD cases caused by contaminated surgical instruments subjected
to conventional methods of cleaning and steam sterilization [4].
Scrapie and CWD differ from other TSEs in that epizootics can be
maintained by horizontal transmission, as well as being mediated
by an environmental reservoir of infectivity [5,6]. Naı ¨ve sheep and
deer have been infected following habitation in environments
contaminated many years prior and, with a lack of evidence for
vector-mediated transmission, environmental fomites have been
implicated in the spread of these diseases [7–9]. Scrapie and CWD
agents can likely enter the environment when shed from infected
animals in saliva, urine or feces or when infected animals die on
the landscape [10,11]. The realization that TSE agents can remain
infectious in the environment has led to the investigation of factors
that could promote agent degradation and limit disease transmis-
sion. Microorganisms, proteases and manganese minerals have all
been suggested to have the potential to reduce prion infectivity on
the landscape or in engineered systems [12–14].
Lichens are symbiotic, plant-like associations between a fungi
(mycobiont) and one, or occasionally more, photosynthetic
partners (photobiont), such as a green alga or cyanobacterium
species [15] and can contain internal bacterial communities
[16,17]. In present day ecosystems, including those inhabited by
CWD-infected animals, lichens are ubiquitous, likely due to their
early colonization of terrestrial environments [18]. Most lichens
live on soil, bark, leaves or wood and can completely cover these
surfaces [15]. Hostile environments, such as arctic tundra,
deserts, bare rock surfaces or toxic slag heaps, are also habitable
by lichens [19–24]. The ability of lichens with algal photobionts
to fix carbon, or for species containing cyanobacteria to fix
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11carbon and nitrogen, increases the range of niches that lichens
can fill [25].
Lichens produce unique and unusual organic compounds that
aid their survival and can have antibiotic, antiviral and other
chemotherapeutic activities [26]. Over 800 of these compounds
have been described and arranged into eight major groups:
depsides, depsidones, dibenzofurans, usnic acids, anthraquinones,
chromones, aliphatic acids, and pulvinic acid derivatives [25], as
well as many minor groups [26]. The production of other types of
biomolecules by lichens remains less well characterized, but an
expanding literature indicates that lichens produce metabolic
enzymes, antioxidant enzymes [27], laccase activity [28,29],
catalase-like enzymes [30] and possibly proteolytic enzymes
[31,32].
In this study, we investigated the ability of lichens to degrade
PrP
TSE in vitro in order to assess the potential that lichens inactivate
prions in the environment. The rationale for this approach is that
the unique biology and diverse biosynthetic capabilities of lichens
may allow these organisms to produce molecules capable of
inactivating or degrading prions. In the current study, we report
that lichen extracts and intact lichens can degrade PrP
TSE in vitro
and the effect is mediated by a serine protease.
Results
Degradation of PrP by lichen extracts
Preparations enriched for PrP
TSE using phosphotungstic acid
(PTA) were treated with lichen extracts or with vehicle as a
control, then examined by immunoblotting using PrP-specific
antibodies 3F4 and SAF84. Extracts of the lichens Parmelia sulcata,
Cladonia rangiferina and Lobaria pulmonaria all reduced the amount
of PrP detected in immunoblots using either antibody (Figure 1A).
Figure 1. Extracts of the lichens P. sulcata, C. rangiferina and L. pulmonaria degrade PrP. Equivalent amounts of PTA-enriched PrP
TSE (30 mg
total protein) were incubated with the indicated lichen extracts (labels, 10 mg lichen equivalents) or with vehicle and were subjected to NuPAGE and
immunoblotting. Extracts of lichens in panel (A) reduced PrP immunoreactivity compared to control, whereas extracts of lichens in panel (B) do not
reduce PrP immunoreactivity. (C) Treatment of PrP
TSE using the method employed in panels (A) and (B) with extracts of isolated algae or
cyanobacterium cultures (10 mg equivalents) do not degrade PrP. (D) Dilutions of control reactions containing PrP
TSE and no lichen extract indicate
that PrP immunoreactivity was no longer detectable when dilution factors were greater than 100. (E) Adding P. sulcata extract to PrP
TSE, but not
allowing it time to react (spiked) did not reduce PrP immunoreactivity compared to control (vehicle). Equivalent samples in which P. sulcata extract
was allowed time to incubate (reacted) did not have detectable PrP immunoreactivity. (F–H) Methods to remove lichen compounds and DMSO from
samples post-reaction, such as (F) washing remaining protein with PBS using a centricon filter column (10–12 kDa MWCO) or (G & H) precipitating
protein using methanol (MeOH) or trichloroacetic acid (TCA) do not restore PrP immunoreactivity. All immunoblots (IB) used anti-PrP mAb 3F4,
except for panel (A) which used both 3F4 and SAF84.
doi:10.1371/journal.pone.0019836.g001
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appears to be species-specific, as extracts of lichens from the
same genera (P. squarrosa, L. quercizans, L. oregano and C. stellaris),
were not able to substantially reduce PrP levels (Figure 1B).
Lichens are classified by the taxonomy of the mycobiont and
within the same genera, lichens commonly have similar or
identical photobionts [15]. We tested extracts of isolated lichen
photobiont algae (Trebouxia anticipata or T. erici) or cyanobacteri-
um (Nostoc edaphicum), but found they were unable to degrade PrP
(Figure 1C), suggesting that the fungal partners of lichens may be
responsible for activity.
The remaining amount of immunoreactivity following treat-
ment of PrP
TSE with P. sulcata, C. rangiferina or L. pulmonaria
extracts, throughout the array of experiments performed here,
ranged from no detectable PrP to a slight band remaining
(Figures 1, 2, 3, 4, 5, 6, 7, 8, and 9). In Figure 1A, we present a
conservative representation of the amount of PrP signal lost: slight
bands are seen in most lanes. Often, however, we observe no
remaining immunoreactivity when treating PrP
TSE with these
lichen extracts. Because lichen extract-treated PrP
TSE samples are
frequently below the detection limit of our assay, we immuno-
blotted a dilution series of PrP
TSE (Figure 1D) to better quantify
the detection limit of our procedures [33,34]. Dilutions of control
samples identical to those in Figure 1A and B (containing PrP
TSE
and vehicle, no lichen extract) were detectable by immunoblotting
until the dilution was increased beyond a factor of 100. These data
indicate that in samples where no PrP was detected following
lichen treatment, PrP levels were reduced by at least two log units.
To control for the possibility that lichen materials in the extracts
inhibited protein separation, transfer or immunodetection, we
compared samples of PrP
TSE that had been reacted with P. sulcata
extract for 1 hr to samples that the extract was spiked into
immediately prior to processing (Figure 1E). As was seen in
Figure 1A, samples in which P. sulcata extract was allowed to react
with the PrP
TSE had substantially reduced PrP immunoreactivity,
whereas there was no loss of signal when the extract was spiked in
and samples were immediately processed (Figure 1E). We tried
additional measures to restore PrP levels (Figure 1F–H). We
attempted to recover immunoreactivity in lichen extract-treated
samples by filtering reactions through a 10–12 kDa molecular
weight cutoff (MWCO) membrane and washing reactions with 50
volumes of phosphate buffered saline (PBS). Lichen extract-treated
samples did not regain immunoreactivity following washing and
vehicle-treated samples had similar amounts of immunoreactivity
whether washed or not (Figure 1F). Similarly, precipitating protein
following reactions with lichen extracts using ice-cold methanol or
tricholoracetic acid did not restore the immunoreactivity lost from
lichen-treated samples (Figure 1G and 1H). These data support
the interpretation that the lichen extracts are degrading PrP
TSE
and not interfering with detection.
Figure 2. Lichen extracts degrade PrP
TSE in brain homogenate. (A) Lichen extracts (10 mg lichen equivalents) were incubated with equal
amounts (10 mL) of 10% brain homogenates from hamsters infected with Hyper (HY) TME, Drowsy (DY) TME or 263K scrapie strains of TSE agents and
PrP degradation was assessed by immunoblotting. Treatment of each hamster brain homogenate with 50 mg?mL
21 of PK demonstrates the presence
of abnormal PrP in the starting material. Using the same conditions as in (A), lichen extracts cause degradation of PrP in (B) a CWD-infected white-
tailed deer, (C) PK-treated HY hamster and (D) uninfected hamster brain homogenates. (E) Protein C5 of the 20S subunit of the proteasome, an
unrelated protein, was also degraded by lichen extracts. Immunoblots (IB) used mAbs 3F4 (A, C and D), 6H4 (B) or pAb anti-C5 (E).
doi:10.1371/journal.pone.0019836.g002
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Enriched PrP
TSE may not have identical physicochemical
properties to PrP
TSE in the brain and different strains of TSE
agents, such as Hyper (HY) transmissible mink encephalopathy
(TME), Drowsy (DY) TME and 263K scrapie, have varying
susceptibly to proteolytic degradation by the serine protease,
proteinase K (PK) [35,36]. We tested the ability of three lichen
extracts to degrade these three strains of hamster TSE agent in BH
(Figure 2A). Each lichen extract diminished PrP levels in BH from
animals infected with each strain of agent and some were reduced
below the limit of immunoblotting detection. Low levels of
immunoreactivity remain post-incubation in the HY samples
treated with P. sulcata extract, whereas DY and 263K are degraded
below the threshold of detection. Both HY and DY samples
treated with C. rangiferina extract retain some immunoreactivity
while 263K was not detected. Extract of L. pulmonaria reduced PrP
below the limit of detection for each strain. Degradation of PrP by
lichen extracts in infected BH samples or PrP
TSE-enriched preps
differs from digestion by PK in that PK cleaves an N-terminal
portion of the PrP
TSE molecule, leaving a truncated end-product,
whereas lichen extracts can reduce PrP immunoreactivity to below
the limit of immunoblotting detection. Similar to these findings,
each extract reduced levels of PrP in CWD-positive deer BH
(Figure 2B); CWD BH samples treated with P. sulcata and L.
pulmonaria no longer possessed PrP immunoreactivity whereas
some, but not all immunoreactivity was lost from C. rangiferina
treated samples.
The PrP in an infected brain exists as a mixture of both PrP
TSE
and cellular prion protein (PrP
C) [37]. We assessed whether lichen
extracts are capable of degrading both isoforms of PrP by
incubating PK-treated, HY-infected BH, which contains only the
disease-associated PrP isoform, PrP
TSE (Figure 2C) or healthy
hamster BH, which contains only PrP
C and no PrP
TSE (Figure 2D)
with P. sulcata, C. rangiferina and L. pulmonaria extracts. We found
Figure 3. Semi-quantitative PMCA to assess RML PrP
TSE
degradation. (A) The extent of mouse RML PrP
TSE degradation was
measured by PMCA analysis of dilutions (10
22–10
26) of vehicle or
L. pulmonaria extract-treated RML. (B) Control reactions lacking PrP
TSE
seed or sonication did not show amplification as measured by PK
digestion. (C) RML samples were incubated with vehicle for 1 hr or with
L. pulmonaria extract (reacted: 1 hr; spiked ,10 sec) then diluted and
subjected to PMCA. Adding L. pulmonaria extract in PMCA reactions
without allowing time for reaction (spiked samples) does not appear to
reduce PrP
TSE levels or affect amplification compared to control
(vehicle). All immunoblots used mAb SAF83.
doi:10.1371/journal.pone.0019836.g003
Figure 4. Effect of lichen extract dose on PrP degradation. (A)
Dose-response of the indicated lichen extracts (0–10 mg lichen
equivalents) on degrading PTA-enriched PrP
TSE (30 mg total protein).
(B) The indicated concentrations of PK (0–10000 mg?mL
21) were
incubated with PTA-enriched PrP
TSE (30 mg total protein) to assess
degradation and for comparison with lichen extracts. Immunoblots
used mAb 3F4.
doi:10.1371/journal.pone.0019836.g004
Figure 5. Effect of pH on PrP degradation by P. sulcata and L.
pulmonaria extracts. Reaction solutions were buffered at the
indicated pHs (5–8) and the effect of each indicated lichen extract
(10 mg lichen equivalents) on degradation of PTA-enriched PrP
TSE
(30 mg total protein) was observed by immunoblotting with mAb 3F4.
doi:10.1371/journal.pone.0019836.g005
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degraded by these extracts. Similar to Figure 2A, we found
complete degradation of both isoforms by P. sulcata and L.
pulmonaria extracts and some remaining immunoreactivity in
samples treated with C. rangiferina extract.
The degree to which a lichen extract degraded PrP did not
necessarily correspond to its activity toward degrading another
unrelated protein in hamster BH (Figure 2E). Following lichen
extract incubation, protein C2 of the 20S subunit of the
proteasome was no longer detectable in P. sulcata extract-treated
samples, but was detected in C. rangiferina and L. pulmonaria-treated
BH. In contrast, L. pulmonaria extract was highly effective at
Figure 6. Common lichen chemicals do not affect PrP levels.
Samples of PTA-enriched PrP
TSE (30 mg total protein) were incubated
with the indicated concentrations of lecanoric acid (LA), usnic acid,
atranorin or vehicle followed by immunoblot analysis with mAb 3F4.
P. sulcata extract (10 mg lichen equivalent) served as a positive control
for PrP degradation.
doi:10.1371/journal.pone.0019836.g006
Figure 7. Assessing enzymatic activity responsible for PrP degradation. Reactions of PTA-enriched PrP
TSE (30 mg total protein) and the
indicated lichen extracts (10 mg lichen equivalents) were prepared with enzyme inhibitors: (A) EDTA (1 or 10 mM) to inhibit metalloenzymes, (B)
ascorbate (5 mM) as an antioxidant and chelator, (C) Cd
2+ (80 mM) to inhibit laccases or (D) a broad-spectrum protease inhibitor cocktail (10 mL per
reaction). The effect of each inhibitor on P. sulcata or L. pulmonaria extract-mediated degradation of PrP was measured by immunoblotting with mAb
3F4.
doi:10.1371/journal.pone.0019836.g007
Figure 8. The serine protease inhibitor Pefabloc SC prevents
PrP degradation. Incubation of PTA-enriched PrP
TSE (30 mg total
protein) with lichen extracts (10 mg lichen equivalents) were performed
in the presence and absence of Pefabloc SC (14 mM). Reactions with
the inhibitor had increased PrP immunoreactivity with mAb 3F4
(reduced PrP degradation).
doi:10.1371/journal.pone.0019836.g008
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C in
uninfected BH (Figure 2D).
Trace amounts of PrP
TSE can be quantified using protein
misfolding cyclic amplification (PMCA), a procedure that uses
sonication to cause PrP
TSE to template conversion of PrP
C to the
infectious form of the protein. To assess the extent of PrP
TSE
degradation in BH of RML strain-infected mice by lichen extracts,
we subjected dilution series of vehicle and L. pulmonaria-treated BH
to a single round of amplification by PMCA (Figure 3A). We were
able to amplify PrP
TSE from vehicle-treated BH at dilutions 10
22
to 10
26, but not at 10
27. In BH treated with L. pulmonaria extract,
we could not detect amplification in samples with dilution factors
greater than 10
24, indicating at least a 100-fold loss of prion
templating activity. Controls in which no PrP
TSE was added or
which were not subjected to sonication did not show amplification
(Figure 3B). We also assessed whether lichen extract, even though
at trace levels in PMCA samples, would inhibit PMCA (Figure 3C).
Samples of RML BH were treated with either vehicle or L.
pulmonaria extract for 1 hr or were spiked with L. pulmonaria extract
and immediately processed for PMCA by dilution into PMCA
buffer. No differences in amplification were observed in vehicle-
treated or lichen extract spiked samples, whereas amplification was
not observed in L. pulmonaria-treated BH at dilutions greater than
10
24. These data are consistent with our immunoblotting results
that show lichen extracts cause at least a two log reduction in PrP
levels.
Dose and pH-dependence of PrP degradation by lichen
extracts
We examined the dose-dependence of P. sulcata and L.
pulmonaria extract-mediated PrP degradation. These lichen extracts
appear to reduce PrP immunoreactivity to a larger extent than
does the C. rangiferina extract. Samples PTA-enriched for PrP
TSE
were incubated with extracts equivalent to 300 mgt o1 0m go f
lichen starting material (Figure 4A). For both lichen extracts, dose-
dependent losses of PrP immunoreactivity were observed. The
highest dose tested of each lichen extract (10 mg lichen equivalent)
was sufficient to reduce immunoreactivity below the threshold of
detection.
We attempted to identify a concentration of PK that would
reduce PrP immunoreactivity to the same degree as the lichen
extracts by incubating PrP
TSE with doses of PK from 50 to
10,000 mg?mL
21. We found that under identical time and
temperature conditions (1 h at 37uC), and in solution buffered to
pH 7.0, which favors PK activity, no tested dose of PK reduced
PrP immunoreactivity below the limit of detection (Figure 4B).
Comparing PrP
TSE samples treated with 50 and 10,000 mg?mL
21
of PK using densitometry, we found that treatment with
10,000 mg?mL
21 reduced immunoreactivity by 73.3% in the blot
shown, whereas both immunoblotting and PMCA experiments
(Figures 1D and 3A, respectively) indicated a greater loss of PrP
immunoreactivity or PMCA activity when treated with lichen
extract.
Figure 9. Intact P. sulcata tissue or a water extract of the lichen degrades PrP. (A) Freshly-collected P. sulcata or P. squarrosa (4 mg, each)
were incubated with infected brain homogenate (100 mL of 10% v/w in distilled water) for 24 h. Following incubation, the lichen-treated brain
homogenates (sup) and the lichen tissues (pel) were analyzed for PrP by immunoblotting with mAb 3F4. A reduction in PrP signal was associated with
P. sulcata, but not with P. squarrosa. (B) PTA-enriched PrP
TSE (30 mg total protein) exposed to chitin beads is bound by the beads, but is extractable
using NuPAGE sample buffer. Little immunoreactivity in the supernatant (sup) shows the protein binds chitin and treatment of bound PrP with
sample buffer yields immunoreactivity approximately equal to PrP starting material. (C) A water extract from P. sulcata, but not P. squarrosa, causes
PrP degradation. Immunoblotting comparison of PTA-enriched PrP
TSE (30 mg total protein) incubated in only water or exposed to a water extract of P.
sulcata (100 mg lichen equivalent) with and without the serine protease inhibitor Pefabloc SC (10 mM). Water extract of P. sulcata induces a
substantial reduction of immunoreactivity that is blocked by PefaBloc SC whereas a water extract of the related lichen P. squarrosa does not degrade
PrP under the same conditions.
doi:10.1371/journal.pone.0019836.g009
Lichen Protease Degrades Prion Protein
PLoS ONE | www.plosone.org 6 May 2011 | Volume 6 | Issue 5 | e19836We also examined the effect of pH on degradation of enriched
PrP
TSE by these extracts (Figure 5). Unbuffered reactions were
found to be at pH 5.6. Over the buffered range from pH 5.0–8.0,
degradation of PrP by P. sulcata extract was enhanced in reactions
buffered to acidic conditions compared to reactions buffered at
pH 8.0. Notably, PrP degradation by L. pulmonaria extract was
equally effective from pH 5.0 to 8.0 (Figure 5) and did not exhibit
pH-dependence at a wider range of pH 4–11 values or when one-
tenth the amount of L. pulmonaria extract was used over the pH
range 4–8 (data not presented). When taken together, these data
suggest concentration and pH can influence P. sulcata-mediated
PrP
TSE degradation whereas L. pulmonaria extract functions at a
wider pH range.
Discerning the Mechanism of PrP Degradation: Lichen
Chemistry and Compounds
Lichens produce a myriad of organic chemical compounds,
some with unusual activities [26]. The chemicals found in
individual lichen species are fairly well known, as they are used
for taxonomical purposes. We compared the known compounds in
P. sulcata, C. rangiferina and L. pulmonaria, as well as those species
found to not degrade PrP (Figure 1B), but did not find a
correlation between PrP degradation and lichen chemistry.
Despite not identifying obvious lichen compound targets, we
incubated PrP
TSE with three common lichen secondary metabo-
lites at varying concentrations to assess whether they would reduce
PrP immunoreactivity (Figure 6). We used atranorin, lecanoric
acid, and usnic acid because they are among the most common
lichen secondary metabolites and are found in the species we
studied. The first two compounds are depsides, while usnic acid is
a dibenzofuran, and all are uniquely produced in lichens. We
incubated PrP
TSE with concentrations of these chemicals equal to,
or higher than, those found in lichen extracts. The highest doses of
each that we tested were near the limit of solubility of each
chemical. We observed that none of the tested lichen secondary
metabolites affected PrP levels in our immunoblots indicating that
they neither degraded PrP
TSE nor caused interference with the
assay.
Discerning the Mechanism of PrP Degradation: Enzymes
Given no clear evidence that lichen secondary metabolites alone
are responsible for the loss of PrP from lichen extract-treated
samples, we hypothesized that degradation was due, at least in
part, to enzymatic activity. We tested whether degradation of
PTA-enriched PrP
TSE could be blocked with inhibitors of various
classes of degradative enzymes found in lichens or fungi [29,30,38]
(Figure 7). The increase in amount of PrP immunoreactivity over
signal found in extract-treated samples lacking inhibitor would
indicate the degree to which the inhibitor prevented PrP
degradation.
The chelator EDTA interferes with the activity of metalloen-
zymes found in fungi such as peroxidases and laccases. Neither 1
nor 10 mM EDTA prevent degradation of PrP by L. pulmonaria
extract (Figure 7A). Similarly, to limit redox reactions and inhibit
some metalloenzymes, we used ascorbate, an antioxidant and
chelator. We found ascorbate (5 mM) did not affect the
degradation of PrP by L. pulmonaria extract (Figure 7B) To inhibit
laccases, we added Cd
2+ (80 mM, final concentration) [39] to
reactions of PrP
TSE with either P. sulcata or L. pulmonaria extract,
but did not observe inhibition of PrP degradation (Figure 7C).
Finally, to test whether degradation was due to protease activity,
we used a protease inhibitor cocktail designed to block many
classes of proteases (Figure 7D). We found that this inhibitor
preserved some PrP immunoreactivity in samples treated with
either P. sulcata or L. pulmonaria extracts, suggesting that one or
more proteases are responsible for degradation. Additionally, we
tested a second protease inhibitor cocktail from a different
manufacturer (Roche) and observed similar results (data not
presented).
To identify the class of protease responsible for degrading PrP,
we screened each of the ten inhibitors included in the Roche
protease inhibitor cocktail for the capacity to prevent PTA-
enriched PrP
TSE degradation. The compounds and concentrations
used are presented in Table 1. We found that only the serine
protease inhibitor, Pefabloc SC, limited PrP
TSE degradation in
samples treated with P. sulcata, C. rangiferina or L. pulmonaria extracts
(Figure 8). Not all starting immunoreactivity is retained in lichen
extract-treated samples containing Pefabloc SC, and the effect is
more prominent on P. sulcata and L. pulmonaria extracts than on C.
rangiferina extract. The inability of other protease inhibitors to
block PrP degradation and the efficacy of Pefabloc SC suggests
that a serine protease is involved in the degradation of PrP by
lichen extract. Our results, however, do not exclude the possibility
that other components of the lichen extract could act synergisti-
cally to degrade PrP.
Degradation of PrP by Intact Lichen Tissue
The previous experiments utilized lichen extracts, and while
they indicate that lichens possess protease activity capable of
degrading PrP
TSE, they do not represent or simulate environmen-
tal conditions in which an intact lichen organism could be in direct
contact with prions in the environment. To examine whether
lichens could degrade PrP under more relevant conditions, we
incubated intact, freshly-collected P. sulcata and P. squarrosa in
solutions of dialyzed HY-infected hamster BH for 24 h at 20uC
and measured PrP levels in BH and lichen tissue (Figure 9A). Our
data show that extracts of P. sulcata cause degradation of PrP
whereas extracts of P. squarrosa do not (Figure 1A and B). We found
that following incubation, PrP levels were reduced in BH
supernatants exposed to P. sulcata, compared to BH incubated
with P. squarrosa or in the absence of lichen. We tested whether
either lichen tissue accumulated PrP and thereby removed it from
the supernatant. No PrP immunoreactivity was detected in either
lichen tissue pellets following homogenization and heating in
NuPAGE lithium dodecyl sulfate (LDS) sample buffer with
reducing agent. As a control for recovery of PrP from lichen
tissues, of which chitin is a major component, we tested whether
PTA-enriched PrP
TSE sorbed to chitin-coated beads could be
Table 1. Protease inhibitors tested to interfere with PrP
degradation by lichen extracts.
Individual Protease Inhibitors Tested Doses
Pepstatin A 0.1–100 mM
Antipain-dihydrochloride 10 mM
Bestatin 1 mM
Chymostatin 1.8 mM
E-64 18 mM
Leupeptin 500 mM
Phosphoramidon 1 mM
Aprotinin 50 mM
Pefabloc SC* 1–50 mM
*Only Pefabloc SC inhibited degradation of PrP by lichen extracts.
doi:10.1371/journal.pone.0019836.t001
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that the PrP was bound by chitin, but that LDS sample buffer was
sufficient to remove most or all of the bound protein. These data
suggest that P. sulcata tissue is capable of degrading PrP
TSE.
Using freshly-collected P. sulcata obtained from two separate
locations approximately 280 km apart, we incubated fresh lichens
with infected BH to assess whether collection site would influence
PrP degradation by P. sulcata. We found that lichens collected at
both sites were capable of degrading PrP and we compared the
remaining PrP immunoreactivity from lichen-treated samples with
non-treated samples (data not presented). There was no significant
difference in effect between P. sulcata collected at either location
(average loss of immunoreactivity of 90610% for Wisconsin Dells
and 80612% for Eagle River; t=20.8, df=14, p=0.45). The
similarity of these values suggested that geographic location may
not affect the capability of P. sulcata to degrade PrP
TSE, at least in
this study. It is worthwhile to note that CWD-infected deer have
been harvested from the same Wisconsin Dells area as the lichen
used in this study was collected. The data in Figure 9A are from
lichens collected at the Eagle River site.
As PrP was degraded by intact P. sulcata tissue, we hypothesized
that the protease could be leached from the lichen and act on the
protein in solution. We, therefore, generated water extracts of P.
sulcata and P. squarrosa and tested whether they would cause
degradation of PTA-enriched PrP
TSE (Figure 9C). We found that,
compared to water alone, PrP levels were reduced when incubated
in the P. sulcata aqueous extract, but that the P. squarrosa extract
fails to cause PrP degradation (Figure 9C), as we had seen in the
acetone extracts (Figure 1A and B). We also found that the serine
protease inhibitor PefaBloc SC prevented complete degradation of
PrP by P. sulcata, consistent with water extracts containing the
same anti-PrP activity found in the lichen organic extract
(Figure 8).
Discussion
The identification of factors in the environment that degrade
prions is critical to our ability to control and mitigate the effects of
scrapie and CWD and understand the fate of prions in natural
environments. In this study, we found that extracts of three lichen
species have a serine protease activity capable of reducing PrP
levels in PrP
TSE-enriched preps or infected BH in vitro.I n
experiments more similar to environmental conditions, we tested
one of those lichen species and found that intact lichen tissue or a
water extract of the tissue could also degrade PrP. The speculated
protein-only nature of the TSE agent has prompted numerous
studies of proteases as potential prion decontaminants [40–45] and
has prompted investigation into their use in soil environments
[46]. Typical conditions used for prion inactivation by proteases,
however, involve elevated temperatures, the presence of detergents
and extreme pH values.
Our discovery that lichens contain proteases capable of
degrading PrP under mild conditions or when lichens are simply
exposed to infected BH in vitro contributes to the repertoire of
potential prion decontaminants. While great caution must be
exercised in extrapolating in vitro studies to environmental
conditions, our data suggest lichens could contribute to prion
degradation on the landscape. If this were the case, inactivation of
prions could occur by direct contact of agent with lichens or
perhaps in soil near lichens. The amount of lichen protease present
in the environment is challenging to estimate and is likely to
depend on its own environmental stability and its propensity to be
leached from lichens. In our study, the quantity of lichen acetone
extract used in reactions represents #10 mg of intact lichen tissue,
a small fraction of a typical specimen, and our findings may
underrepresent the ability of lichens to degrade prions shed
directly onto lichen surfaces. The extractability of proteases from
lichens in the environment is unknown, but our data show that a
water extract of P. sulcata contains prion-degrading protease
activity (Figure 9C) and suggest the potential of its presence in
lichen leachate. Previous work has indicated that water is a
suboptimal extractant for lichens [28,47,48] and our own studies
indicate that ten-fold more lichen tissue is needed to produce an
aqueous extract with protease activity than with acetone. Despite
limited extractability by water, lichen chemicals can be found in
leachates and soil; usnic acid, for example, was found in soil under
lichens at 1–4 ppm [49]. Should the lichen protease be present at
similar or higher levels, and be active, it is conceivable that lichen
leachates could influence the survival of prions in the environment.
When treated with lichen extracts, even at doses not sufficient to
degrade all PrP, PrP
TSE does not appear to undergo the N-
terminal cleavage observed with PK treatment (Figures 2 and 3).
Analysis of residual PrP immunoreactivity following lichen extract
treatment using antibodies to various epitopes capable of
recognizing PrP
TSE from multiple species suggests degradation of
PrP, rather than alteration of the protein to a form unrecognized
by a particular antibody. Additionally, inhibition of PrP
degradation by PefaBloc SC, a serine protease inhibitor, suggests
that proteolysis is a major factor responsible for PrP degradation
by lichen extracts, but may not be the only factor. It is noteworthy
that PK, another serine protease, even at high concentrations, like
1.6 mg?mL
21 [50] or 10 mg?mL
21 (Figure 4B), was not capable
of degrading PrP
TSE to the same extent as the crude lichen extract
we examined (Figure 3B). Previous work suggests that longer
incubation periods may be necessary for PK to degrade PrP
TSE to
the same degree that we have found with lichen extracts [51,52].
Purified or concentrated lichen protease could be expected to
promote even more PrP
TSE degradation than lichen extracts, but
further investigation is needed to identify if other components or
enzymes in the lichen extracts may synergize with the serine
protease to promote PrP
TSE degradation.
Our current investigation has focused on the degradation of
PrP
TSE and, clearly, investigation into the effect of lichen proteases
on TSE infectivity is a critical next step. Studies have observed
dramatic losses in PrP levels but with minimal effect on infectivity
[53,54]. Conversely, lichen extracts may diminish prion infectivity
by affecting prion stability, structure or replication without reducing
the total amount of PrP [55]. The PrP degradation activity observed
in each lichen extract may reflect the quantity of protease present or
amounts of required cofactors; the contribution of lichen secondary
metabolites to the degradation of PrP remains unclear. Lichen
organic, and potentially water, extracts can be rich in secondary
metabolites that often have potent activities [56–58]. While, our
findings suggest that a serine protease is a major contributor to PrP
degradation, our data does not exclude the possibility that lichen
secondary metabolites may function as cofactors for lichen enzymes
or even sensitize PrP to protease digestion.
The pH-dependence of P. sulcata extract and the unaltered PrP
degradation by L. pulmonaria extract across a wide range of pH
values points to the existence of differences in proteolytic
mechanisms among lichen species. The specificity of whether or
not a given lichen species extract can degrade PrP appears to be
due to the mycobiont component of the lichen, as extracts of close
relatives of P. sulcata, C. rangiferina and L. pulmonaria with the same
or similar photobionts did not display this activity. Identical lichen
species collected at different times or locations performed
identically with respect to PrP degradation, further supporting
the concept of species specificity.
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proteases in lichens. Shapiro et al. detected protease activity in six
lichen species by amine production and compared it with
nitrogenase activity in order to evaluate protein synthesis and
degradation [32]. No information was provided in this study
regarding whether photobionts or mycobionts were responsible for
the protease activity. Avalos et al. found evidence indicating
photobiont hydrolase activation in the lichen Evernia prunastri [31].
Our examination of extracts from common lichen photobionts
suggests that the proteolytic activity in our extracts could be due
solely to the mycobionts. The lack of PrP degrading activity in
related species that possess similar or identical photobionts
(Figure 1B) further supports the role for the mycobiont in PrP
degradation. Our data does not exclude, however, that photo-
bionts living in symbiosis with the mycobiont may behave
differently than the free-living organisms. In both the photobiont
and the mycobiont, symbiosis would be expected to differentially
regulate the production of various gene products and may affect
the production of the proteolytic activity capable of degrading PrP.
An expanding literature suggests that lichens can host a range of
bacterial species that impact growth and metabolic characteristics
of the myco and photobionts [16,17]. Our data also do not exclude
the possibility that lichen-associated bacteria could contribute to
the degradation of PrP and further investigation into what
organism is contributing the degradative activity is needed.
The question of why a lichen protease would be capable of
degrading PrP
TSE is intriguing. Yeast can be infected by a number
of fungal prions with different amino acid sequences than
mammalian prions [59], but lichen mycobionts have not, to our
knowledge, been examined as potential hosts. Mammalian and
fungal prions share a common amyloid structure [60], suggesting
that lichen proteases may have activity against fungal prions as
well. The presence of an enzyme capable of degrading PrP
TSE in
lichens could suggest protection against prions or amyloids favors
some aspect of lichen survival.
Interactions between lichens and wildlife are well documented
[61]. The most well known examples are reindeer foraging on
lichen mats in the boreal zone and the recent elk mortality events
due to consuming toxic amounts of lichens in Wyoming [62]. It is
not unreasonable to hypothesize that dietary lichens could affect
CWD transmission or pathogenesis in cervids. Our data argue that
investigation of these putative interactions is warranted, as is
further characterization of the mechanism of PrP degradation by
lichens, including identification of responsible enzymes and any
potential cofactors.
Materials and Methods
Lichens, Isolated Photobionts and Extracts
The lichen species selected for study were: Parmelia sulcata from
Isle Royale, Michigan (collected in 1999) or from Wisconsin Dells
or Eagle River, Wisconsin (collected in 2008 or 2009, respectively);
P. squarrosa from the Superior National Forest (NF), Minnesota
(1999) or from Eagle River Wisconsin (collected in 2009 and
2010); Cladonia rangiferina from Isle Royale (1999); C. stellaris from
Superior NF (1999); Lobaria pulmonaria and L. quercizans from
Superior NF (1999), and L. oregana from the Oregon coast (2002).
These species differ in morphology, myco- and photobionts and
habitat: Parmelia spp. are often found growing on trees and rocks,
Cladonia spp. are a common ground cover and Lobaria spp. typically
grow on trees. Lichens were preserved at room temperature either
in a desiccated and stable dormant state in opaque, breathable
bags from the date of collection or as a ground powder in plastic
bags.
Dried lichens were powdered using a Retsch mixer mill MM
200 (Newtown, PA) in polytetrafluoroethylene grinding jars.
Extracts were produced by suspending lichen powders in acetone
at 10% (w/v) and incubating at 37uC for 24 h with vigorous
shaking. Following incubation, solid particles were removed by
filtration through Whatman filter paper (Grade #1, Piscataway,
NJ), and the acetone in the filtrate was evaporated. The remaining
residue was resuspended in dimethyl sulfoxide (DMSO) (Thermo-
Fisher Scientific, Rockford, IL) such that each g of lichen powder
starting material would yield 1 mL of product.
Isolated lichen photobionts (Nostoc edaphicum, Trebouxia anticipata
and T. erici) were purchased from the UTEX Culture Collection of
Algae (University of Texas, Austin, TX) and were grown as agar
cultures according to directions supplied by the Culture Collec-
tion. Following 8 weeks of growth, photobionts were collected and
powdered using liquid nitrogen. Extracts were produced by
suspending powders in acetone at 10% (w/v) and processing as
described earlier for production of lichen extracts.
Water extract of P. sulcata or P. squarrosa was prepared by placing
1 g of intact lichen into 10 mL of deionized water and shaking for
24 h at 20uC. Following incubation, particles were removed by
centrifugation at 5000 g for 5 minutes and water extracts were
collected by pipette.
Source of Prion Protein and brains
All animal work was conducted with approval of the National
Wildlife Health Center institutional animal care and use
committee (Protocol #EP080716). Hamster PrP
TSE was generated
by the experimental infection of Syrian golden hamsters with the
HY or DY strains of hamster-passaged TME agent or 263K strain
of hamster-passaged scrapie [63,64]. The HY strain of TME from
hamsters is used in all experiments unless another specific agent is
listed. Uninfected brains were from animals never experimentally
challenged or exposed to areas where prion-challenged animals
were housed. White-tailed deer CWD agent was obtained from
the obex of a hunter-harvested G96 Prnp genotype (GenBank
accession number AF156185) animal [65,66]. The RML strain of
mouse-passaged scrapie was generated by experimental infection
of CD-1 mice.
Brain homogenate (BH) was made by adding brain tissue to a
final concentration of 10% (w/v) in PBS and homogenizing in a
Dounce homogenizer. Some experiments used BH that was
dialyzed using Slide-A-Lyzer cassettes (10–12 kDa MWCO;
ThermoFisher Scientific) against three changes of deionized water
over a 24-h period. Proteinase-K (PK)-treated BH was generated
from 10% HY-infected BH treated with 50 mg?mL
21 PK
(Promega, Madison, WI) for 1 hr at 37uC. Activity of PK was
blocked with 1 mM PefaBloc SC (Roche Applied Science,
Germany) on ice and then frozen prior to use. Phosphotungstic
acid (PTA)-enriched PrP
TSE preparations were produced using
published methods [67]. Briefly, 4% PTA (Sigma-Aldrich, St.
Louis, MO) in a 170 mM MgCl2, pH 7.4 solution was added to
5% BH in 2% sarkosyl to a final concentration of 0.25% PTA.
Homogenate was incubated at 37uC for 24 h then centrifuged at
16000 g for 30 min. Pellets derived from 1 g of brain tissue were
pooled and resuspended in 3 mL of deionized, ultra-pure H2O
and were dialyzed against three changes of deionized, ultra-pure
H2O (MWCO 10–12 kDa) over 24 h to remove small molecular
weight contaminants.
Lichen extract reactions
Degradation of PrP by lichen extracts was assessed either using
preparations enriched for PrP
TSE (PTA-enriched PrP
TSE) or PrP
in a complex matrix of brain materials. BH (10 mL; 1 mg brain
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TSE preparation (10 mL; 30 mg
total protein) was incubated with 10 mL of lichen extract in
DMSO (10 mg of lichen equivalent) and 10 mL of deionized H2O
at 37uC for 1 h. Control reactions contained 10 mL of DMSO
vehicle rather than lichen extracts or contained lichen extract, but
were not allowed to incubate (‘‘spiked’’). For dose-response
experiments employing smaller amounts of lichen extracts, the
remaining volume was compensated with DMSO. For experi-
ments investigating the effect of pH on PrP
TSE degradation by
lichen extracts, 100 mM sodium acetate (pH 5), 100 mM sodium
citrate (pH 6) or 100 mM Tris (pH 7 and 8) replaced water in
reactions. In enzyme inhibitor experiments, final inhibitor
concentrations were: 5 mM ascorbate, 80 mM Cd
2+, and 1 or
10 mM EDTA. Protease inhibitor cocktail (Sigma-Aldrich, St.
Louis, MO) was used at 10 mL per reaction, PefaBloc SC was at
10–14 mM and all other protease inhibitors were at the
concentrations listed in Table 1.
For experiments with P. sulcata water-extract, 10 mL of PTA-
enriched PrP
TSE was added to 990 mL of water, lichen water-
extract (,100 mg lichen equivalent) or lichen water-extract in the
presence of PefaBloc SC (10 mM) and was shaken for 1 hour at
20uC. Following incubation, protein was precipitated with
trichloroacetic acid (TCA) and pellets were resuspended in
100 mM Tris, pH 7.0.
Methods to clean-up samples in an effort to recover PrP
immunoreactivity included precipitating 30 mL reactions contain-
ing equal parts of PrP
TSE, water and lichen extract or DMSO with
4 volumes of ice-cold methanol or TCA. Other samples were
diluted with 470 mL of PBS and placed in microcentrifuge
concentrating/desalting columns (Centricon, 10 kDa MWCO;
Millipore, Billerica, MA) and subjected to centrifugation. When
sample volumes were reduced, the material on the filter was
washed 3 times with 500 mL of PBS prior to recovery of the
remaining PrP into a clean microfuge tube. Reactions to be
analyzed by immunoblotting were halted by the addition of 46
lithium dodecyl sulfate (LDS) sample buffer and 106 NuPAGE
reducing agent (Invitrogen, Carlsbad, CA), each to final
concentrations of 16, and were then heated at 95uC for 5 minutes.
PK digestion
Samples of PrP
TSE were incubated with 20 to 10,000 mg?mL
21
PK in 33 mM Tris (pH 7.0) for 1 h at 37uC. Following incubation,
digestion reactions were halted by additions of 46 LDS sample
buffer and 106 NuPAGE reducing agent, each to final
concentrations of 16, and were then heated at 95uC for 5 minutes.
Lichen chemical-PrP
TSE reactions
The lichen secondary metabolites usnic acid, atranorin (both
from Sigma-Aldrich, St. Louis, MO) and lecanoric acid (the
generous gift of D. Fahselt) were dissolved in DMSO to final
concentrations of 3, 10 or 100 mg?mL
21. Compounds were added
to PTA-enriched PrP
TSE preparation (10 mL) in the presence of
10 mL of deionized, ultra-pure H2O and incubated at 37uC for
1 h. Samples were then treated with LDS sample buffer and
reducing agent and heated 95uC for 5 minutes.
Live lichen-BH incubation
Freshly collected lichen tissue was air dried for $48 h prior to
placing an intact 4 mg portion into 100 mL of dialyzed, HY BH.
Lichen-BH samples were incubated at 20uC for 24 h with
agitation. Samples lacking lichen tissue served as controls.
Following incubation, the BH was removed from the lichen tissue
by micropipette and 30-mL aliquots of lichen-treated and control
BH were analyzed by immunoblotting. Lichen tissue, after
exposure to BH, was ground in 16NuPAGE sample buffer with
reducing agent using a rotary pestle and then heated at 95uC for
5 min. Lichen particles were precipitated by a touch spin in a
microfuge while the samples were still hot, and the sample buffer
was collected and promptly subjected to NuPAGE and immuno-
blotting.
Extraction of PrP from chitin
To assess extractability of PrP
TSE from lichens, 10 mL of PrP
TSE
was added to 100 mL of chitin-coated magnetic beads (New
England BioLabs, Ipswich, MA) in a final volume of 1 mL in
distilled H2O. Control samples lacking beads and chitin bead
samples were incubated for 24 h at 20uC with shaking. Beads were
removed from solution by magnet and protein in the remaining
solutions was precipitated with 4 volumes of ice-cold methanol.
Extraction of beads and resuspension of the pellets was
accomplished with 16NuPAGE sample buffer.
Protein Misfolding Cyclic Amplification (PMCA)
All PMCA procedures were performed according to the method
described in Fujihara, et al. [68]. Following incubation of RML-
infected BH with L. pulmonaria extract (for either 1 hr or spiked
into the sample for the minimum time possible) or vehicle, each
sample was divided into two aliquots; one aliquot was prepared for
immunoblotting as described above and one aliquot was serially-
diluted in PMCA buffer (150 mM NaCl, 1 mM EDTA, 50 mM
HEPES pH 7.0, 1% Triton X-100, 0.05% digitonin and EDTA-
free protease inhibitor cocktail; Roche Applied Science, Ger-
many). Substrate for PMCA was the supernatant from previously-
frozen, healthy CD-1 mouse brain tissue homogenized to 10% (w/
v) in PMCA buffer and centrifuged at 2000 g for 2 min. Reactions
were held in snap-cap 200 mL PCR tubes and the reaction mixture
was composed of 79 mL substrate and 1 mL of seed (e.g., dilutions
of L. pulmonaria extract-treated, L. pulmonaria extract-spiked or
vehicle-treated infected BH). Amplification was performed using a
deep-well cup-horn Misonix sonicator (Model 3000; Farmingdale,
NY) attached to a circulating water supply in an incubator set to
37uC. Sonication for 20 s every 30 min at 60% power was
performed for 48 h. As controls, reactions containing substrate
without infected BH seed were also subjected to cycling and
samples containing substrate and infected BH were held at 37uC
without cycling, but neither showed amplification. Following
PMCA, samples were treated with 20 mg?mL
21 PK, and an
aliquot was analyzed by NuPAGE and immunoblotting.
NuPAGE and immunoblotting
Samples were subjected to 12% NuPAGE gel electrophoresis
using MOPS running buffer and electroblotted to polyvinyl
difluoride membranes. Membranes were then immunoblotted
using monoclonal antibodies (mAb) 3F4 (1:20000), SAF83 (1:5000)
and SAF84 (1:200) (Chemicon, Billerica, MA), 6H4 (Prionics AG,
Switzerland, 1:10000) or polyclonal antibody (pAb) rabbit anti-20S
proteasome subunit C2 (1 mg?mL
21; A.G. Scientific, San Diego,
California). Anti-mouse and anti-rabbit secondary antibodies
conjugated with horseradish peroxidase were used to detect mAbs
and the pAb, respectively (Santa Cruz Biotech, Santa Cruz, CA).
Visualization was performed using Pierce (Rockford, IL) Super-
Signal West Pico Chemiluminescent Substrate System and an EC3
imaging system (UVP, Upland, CA). For presentation purposes,
some irrelevant lanes were excised from images of membranes and
no further changes to brightness or contrast were made following
excision. Data from separate gels presented in the same figure are
separated by a black line or presented in a separate box. All
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experimental replicates done in separate reaction tubes.
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